[Translation] A randomized, double-blind, controlled phase III bridging clinical study to evaluate the efficacy of Uproleselan combined with chemotherapy versus chemotherapy alone in the treatment of Chinese subjects with relapsed or refractory acute myeloid leukemia
本研究的主要目的是比较接受Uproleselan联合化疗与单纯化疗的受试者的总生存期(OS)。
[Translation] The primary objective of this study was to compare the overall survival (OS) of subjects who received Uproleselan plus chemotherapy versus chemotherapy alone.